PK-LIVE NEWS

WASHINGTON, UNITED STATES — October 16, 2026: The United States has recorded 4,410 measles cases in 2026 as the highly contagious disease continues to spread across the country, according to the latest figures from the Centers for Disease Control and Prevention (CDC). The total, reported as of October 15, represents an increase of 330 cases compared with the previous weekly update, highlighting the continuing challenge facing public health authorities. The growing outbreak has raised concerns about vaccination coverage, hospital admissions and the potential for further transmission in communities where immunity against the disease is insufficient. Health officials are monitoring infections across multiple states while encouraging eligible individuals to ensure that their vaccinations are up to date. Measles is a highly infectious viral disease that can spread rapidly among people who have not developed immunity. Although many patients recover, the infection can cause serious complications, including pneumonia and inflammation of the brain. Young children, unvaccinated individuals and people with weakened immune systems may face a greater risk of severe illness. The latest figures underline the importance of early detection, vaccination and public awareness as authorities work to contain the outbreak. More Than 4,400 Cases Reported Nationwide The CDC’s latest reported total of 4,410 cases marks a further increase in the national measles burden. The additional 330 cases reported over the preceding week indicate that transmission remains active and that public health agencies continue to face challenges in containing the virus. The United States had reported 2,289 confirmed measles cases during the whole of 2025. The 2026 total has already substantially exceeded that figure, demonstrating the scale of the current resurgence. The CDC collects national data from state and local health departments, which investigate suspected infections and report confirmed cases. Reporting schedules can differ between jurisdictions, meaning figures may be updated as new laboratory results and investigations become available. The national total includes confirmed cases among US residents and international visitors. Public health officials use these reports to monitor transmission patterns, identify outbreaks and determine where additional prevention measures may be required. The continuing rise in infections has renewed attention on the importance of maintaining high vaccination rates, particularly among schoolchildren and communities experiencing active transmission. Pennsylvania Emerges as a Major Outbreak Hotspot Pennsylvania has become one of the most closely watched locations in the current outbreak. State health department figures showed 1,222 measles cases as of October 14, alongside 225 disease-related hospitalisations. The outbreak has placed additional demands on public health authorities, healthcare facilities and local communities. Officials are monitoring infections and encouraging residents to take preventive measures, particularly when cases are reported in schools, households or other settings where people have close contact. The state has also reported measles-related deaths. However, the number publicly attributed to the disease by Pennsylvania authorities has differed from the national figure reported by the CDC, reflecting differences in how deaths are reviewed and classified. The CDC has confirmed two measles-associated deaths nationally in 2026 under its current reporting approach, while Pennsylvania has reported five measles-related deaths. The difference has prompted questions about the process used to determine whether measles contributed to a person's death. Measles can lead to fatal complications, and determining the underlying cause of death may require medical records, laboratory results and examination of other health conditions. The figures may therefore change as investigations and reviews continue. The situation in Pennsylvania illustrates how a concentrated outbreak can create significant pressure on healthcare services while raising broader questions about surveillance and the consistency of public health reporting. Hospitalisations Highlight the Seriousness of Measles The CDC reported 451 measles-related hospitalisations across the United States in 2026. Although not every infection results in severe illness, the number of hospital admissions demonstrates that the outbreak is creating a substantial burden for some patients and healthcare providers. Measles typically begins with symptoms such as a high fever, cough, runny nose and red, watery eyes. A characteristic rash usually develops after the initial symptoms and can spread across the body. Some patients recover without major complications, but others may develop ear infections, diarrhoea, dehydration, pneumonia or encephalitis, which is inflammation of the brain. These complications can require hospital treatment and, in severe cases, may result in long-term health problems or death. Infants, young children, pregnant women and people with weakened immune systems may require particular attention because of their increased vulnerability to complications. Medical professionals advise people who suspect they have measles to contact a healthcare provider before arriving at a clinic or hospital. Calling ahead can help healthcare teams take precautions to reduce the risk of exposing other patients and staff. Vaccination Remains the Main Prevention Measure Vaccination remains the principal tool for preventing measles infections and reducing the risk of large outbreaks. The measles, mumps and rubella (MMR) vaccine is widely used to protect against measles and two other viral diseases. According to the CDC, two doses of the MMR vaccine are approximately 97 per cent effective at preventing measles, while one dose is approximately 93 per cent effective. The CDC's data indicate that the overwhelming majority of reported cases in 2026 have involved people who were unvaccinated or whose vaccination status was unknown. This pattern highlights the importance of checking immunisation records and ensuring that eligible individuals receive recommended doses. Vaccination protects individuals and also helps reduce the likelihood that the virus will spread through schools, households and other community settings. When vaccination coverage falls, the virus can spread more easily among susceptible people. Parents and caregivers should consult healthcare professionals about their children's vaccination schedules, particularly if their children attend schools or childcare facilities where exposure has been reported. Adults who are unsure about their vaccination history can also ask a healthcare provider whether they need additional protection. People should not assume that a previous mild illness provided immunity. A healthcare professional can advise on vaccination and appropriate precautions based on a person's age, medical history and circumstances. Why Measles Spreads So Easily Measles is among the most contagious infectious diseases. The virus spreads through the air when an infected person breathes, coughs or sneezes. It can remain infectious in the air for a period after an infected person has left an enclosed space, allowing others to become exposed without direct physical contact. An infected person can transmit the virus before the characteristic rash appears, making early identification more difficult. This can allow the disease to spread before a patient realises that the symptoms are consistent with measles. Crowded indoor environments, schools, childcare facilities and households can provide opportunities for transmission when susceptible people come into contact with the virus. Public health agencies may respond to confirmed cases by identifying people who were exposed, notifying affected communities and providing guidance on vaccination and monitoring for symptoms. These measures can help identify additional infections and limit further spread. People who have been exposed should follow instructions from their local health department or healthcare provider, especially if they are unvaccinated, pregnant or immunocompromised. Declining Vaccination Coverage Raises Concerns The current outbreak has renewed debate about declining vaccination coverage and the role of public confidence in public health programmes. Measles was declared eliminated from continuous transmission in the United States in 2000, a milestone made possible by sustained vaccination efforts. However, elimination did not mean that the virus disappeared worldwide or that the United States could no longer experience outbreaks. Infections can be introduced through international travel and spread within communities where vaccination coverage is inadequate. The CDC has identified lower MMR vaccination coverage among kindergarten students as one factor contributing to the risk of outbreaks. Coverage has fallen below the national target of 95 per cent, while some communities have substantially lower rates. When vaccination rates decline, outbreaks can become more difficult to control. Health experts therefore emphasise access to reliable information, routine immunisation and timely responses to confirmed cases. Public health officials also face the challenge of communicating accurate information about vaccine effectiveness and safety. Clear guidance from healthcare professionals can help families understand the benefits of vaccination and make informed decisions. What Happens Next? The CDC and state health departments are continuing to monitor reported infections, hospitalisations and outbreaks. Their response may include investigations, public information campaigns, vaccination efforts and support for communities experiencing a rise in cases. The number of confirmed infections may continue to change as additional cases are investigated and reported. Differences between national and state figures can also arise because of reporting schedules and the criteria used to classify certain outcomes. The scale of the outbreak will depend partly on how quickly infections are identified, whether vaccination gaps are addressed and how effectively local health authorities can limit transmission. For the public, the central message is to remain informed, check vaccination records and seek professional medical advice when symptoms or possible exposure raise concerns. People experiencing symptoms consistent with measles should contact a healthcare provider before visiting a medical facility in person. Conclusion The United States has reported 4,410 measles cases as of October 15, 2026, with 451 hospitalisations recorded this year. Pennsylvania remains a major hotspot, while differences in the reporting of measles-related deaths have added another issue to the public health response. The outbreak demonstrates that measles remains a serious health risk when vaccination coverage is insufficient. Continued surveillance, timely medical assessment, public awareness and recommended vaccination will be important in limiting further transmission and protecting vulnerable communities. PK-News.com will continue covering major international health developments, disease outbreaks and public safety updates as new information becomes available. Developed, Researched & Published by PK-News.com PK-News Digital News & Research Desk Pakistan & World News | Health News | Medical Updates | Science & Technology Founder & Lead Architect: Muhammad Ibraheem | PK-News.com

WASHINGTON, UNITED STATES — October 16, 2026: Women experiencing hot flashes, night sweats, sleep disturbances and other symptoms associated with menopause may have access to a broader range of treatment options following new guidance from the American College of Obstetricians and Gynecologists (ACOG). The updated recommendations mark a significant development in menopause care, placing greater emphasis on evidence-based treatment, individual medical needs and informed discussions between patients and healthcare professionals. The guidance is the organisation’s first major update on menopause treatment since 2014. It highlights menopausal hormone therapy as an important option for eligible women while also recognising nonhormonal medicines and other approaches that may help manage symptoms. The recommendations reflect a growing emphasis on treating menopause as a stage of life in which symptoms can be managed rather than something women must simply endure. Understanding Menopause and Its Symptoms Menopause is a natural biological transition that generally occurs between the ages of 45 and 55, although the timing varies. It is commonly identified after a woman has gone 12 consecutive months without a menstrual period for reasons unrelated to another medical condition. The years leading up to menopause, known as perimenopause, can also bring substantial physical and emotional changes. During this transition, changes in estrogen and other reproductive hormones can affect the body's temperature regulation, sleep, mood and vaginal health. Some women experience only mild symptoms, while others face repeated hot flashes, intense night sweats, fatigue and difficulty concentrating. Hot flashes can cause a sudden sensation of heat, often accompanied by sweating, flushing, a rapid heartbeat or chills. When these episodes occur during sleep, they can wake women repeatedly and contribute to insomnia, daytime tiredness and reduced quality of life. Symptoms can also affect work, relationships and everyday activities. Medical professionals increasingly encourage women experiencing persistent or disruptive symptoms to seek advice instead of assuming that discomfort is unavoidable. Hormone Therapy Gains Greater Attention One of the central elements of the updated guidance is the role of menopausal hormone therapy, also called hormone replacement therapy. This treatment uses hormones to address symptoms associated with declining estrogen levels and can be highly effective for hot flashes and night sweats in appropriately selected patients. For women who have a uterus, systemic hormone therapy generally combines estrogen with a progestogen. The progestogen helps protect the lining of the uterus against excessive growth that can occur when estrogen is taken alone. Women who have had their uterus removed may be eligible for estrogen-only therapy, depending on their medical history and individual circumstances. Hormone therapy is available in different forms, including tablets, skin patches, gels and sprays. The most appropriate option depends on factors such as symptoms, personal preferences, medical history and the potential benefits and risks of different formulations. The updated recommendations encourage healthcare professionals to assess each patient's circumstances rather than treating all women experiencing menopause in the same way. However, hormone therapy is not suitable for everyone. Certain medical histories, including some hormone-sensitive cancers, blood clots, stroke, heart disease and liver conditions, may make particular treatments inappropriate. Unexplained vaginal bleeding also requires medical evaluation before treatment decisions are made. Women should therefore discuss their health history and individual risk factors with a qualified clinician before starting, changing or stopping hormone therapy. Newer Nonhormonal Medicines Offer Additional Choices The guidance also highlights nonhormonal treatments for women who cannot use hormone therapy, prefer not to take it or need alternatives because of their medical circumstances. One option is fezolinetant, sold under the brand name Veozah in the United States. It works by targeting a pathway in the brain involved in regulating body temperature and can reduce moderate to severe hot flashes. Another medicine, elinzanetant, marketed as Lynkuet, was approved in the United States in 2025. It acts on neurokinin receptors involved in temperature regulation and sleep-wake processes, offering another option for certain women experiencing menopausal symptoms. Other medicines, including selected antidepressants and gabapentin, may also be prescribed to help manage symptoms in appropriate circumstances. These medications work differently and can have side effects or interactions, so treatment decisions should be made with a healthcare professional. The expanded range of treatments is important because some women have medical conditions that make systemic hormone therapy unsuitable. For example, women with a history of certain breast cancers may require specialised advice and nonhormonal approaches. The availability of alternatives also means that women do not necessarily have to choose between hormone therapy and receiving no medical help. A clinician can discuss available options based on symptoms, health history and personal priorities. Insomnia and Sleep Problems Require Attention Sleep disturbances are among the most frustrating problems associated with menopause. Night sweats can repeatedly interrupt sleep, leaving women tired, irritable and less able to concentrate during the day. The new guidance recognises the importance of selecting treatments according to the symptoms a patient experiences. If sleep disruption is closely linked to hot flashes and night sweats, treatment that reduces these episodes may help improve sleep. However, not every sleep problem during midlife is caused by menopause. Conditions such as sleep apnoea, restless legs syndrome, anxiety and chronic insomnia may also contribute to disrupted rest. Healthcare professionals may therefore need to assess other possible causes before recommending treatment. Addressing sleep problems directly can be important when symptoms continue even after hot flashes improve. Women can also discuss practical measures such as maintaining regular sleep times, keeping the bedroom comfortably cool and limiting factors that worsen their individual symptoms. These measures may support treatment, although they are not a substitute for medical assessment when symptoms are severe or persistent. Lifestyle Approaches and Psychological Support Medication is not the only way to manage menopause symptoms. The updated guidance recognises approaches such as cognitive behavioural therapy, mindfulness-based interventions, exercise and other supportive strategies that may help certain women. Cognitive behavioural therapy can help people manage the effects of symptoms on sleep, stress and daily functioning. Regular physical activity supports general health, while a balanced diet and healthy sleep habits can contribute to overall wellbeing. Some women may also explore clinical hypnosis or acupuncture after discussing the potential benefits and limitations with a healthcare professional. Evidence varies across these approaches, and they should not automatically be considered equivalent to treatments with stronger evidence for relieving hot flashes. A personalised plan may combine medication with lifestyle changes and psychological support. The right balance will depend on symptom severity, health considerations, treatment preferences and the extent to which symptoms interfere with daily life. Why Individualised Menopause Care Matters The updated recommendations underline the importance of shared decision-making between patients and clinicians. Rather than assuming that one treatment is appropriate for every woman, healthcare professionals are encouraged to explain the available options, expected benefits, potential side effects and relevant safety considerations. Age and the timing of menopause can influence the balance of benefits and risks associated with hormone therapy. For many otherwise healthy women who are younger than 60 or within 10 years of menopause onset and have no contraindications, hormone therapy may offer substantial relief from disruptive symptoms. Nevertheless, eligibility must be assessed individually. Personal and family medical history, previous treatments, the presence of a uterus and the patient's goals can all influence the choice of therapy. Women should also be cautious about exaggerated claims circulating online. Hormone therapy can be beneficial for many patients, but it is not a universal solution for every symptom or every medical history. Reliable medical advice can help patients make informed choices. What Women Should Know The updated guidance represents a broader approach to menopause care, combining hormone therapy with newer nonhormonal medicines and supportive interventions. It reflects growing recognition that hot flashes, night sweats, insomnia and other symptoms can substantially affect quality of life. Women experiencing disruptive symptoms should speak with a qualified healthcare professional about their options rather than starting medication on their own. A clinician can determine whether symptoms are related to menopause, assess relevant risks and recommend a suitable treatment plan. The recommendations do not mean every woman needs medication or hormone therapy. Instead, they encourage women and clinicians to consider the full range of options and choose care according to individual circumstances. Conclusion The latest ACOG guidance signals an important shift towards more personalised menopause treatment. With hormone therapy remaining an effective option for eligible women and additional nonhormonal medicines available, patients may have more choices for managing hot flashes, night sweats and sleep problems. Careful medical assessment and informed discussions remain essential to finding the safest and most appropriate approach. Developed, Researched & Published by PK-News.com PK-News Digital News & Research Desk Pakistan & World News | Health News | Medical Updates | Science & Technology Founder & Lead Architect: Muhammad Ibraheem | PK-News.com

Government Says No Authorization Has Been Granted as Ethical Concerns Grow Over Proposed Study Involving Thousands of Babies Developed, Researched & Published by PK-News.com PK-News Digital News & Research Desk BISSAU, GUINEA-BISSAU — October 14, 2026: Guinea-Bissau’s transitional government has denied approving a controversial clinical trial involving the hepatitis B vaccine in newborn babies, raising fresh questions about the future of a proposed research project that has attracted international attention and serious ethical concerns. The government’s announcement followed reports suggesting that the United States-funded study had received permission to proceed in the West African country. Health Minister Quinhin Nantote clarified that the government had not authorized the trial, emphasizing that research involving human participants, particularly newborn children, must comply with national laws, scientific review procedures and internationally recognized ethical standards. The clarification has renewed debate over the responsibilities of governments, researchers and international funding institutions when conducting medical studies involving vulnerable populations. Government Demands Proper Review Guinea-Bissau’s health authorities have stressed that no clinical research involving children should proceed without the appropriate regulatory authorization and ethical safeguards. The health minister’s statement also highlights the importance of national oversight when foreign institutions propose medical research within another country. The disagreement over the study’s approval status emerged after earlier reports indicated that the project could move forward. Questions had already been raised about whether the research protocol had undergone all the necessary reviews and whether its design adequately protected participating infants. The government has not provided a detailed timetable for the next steps in the review process. The study’s future therefore remains uncertain. What the Proposed Vaccine Trial Involves The proposed study is designed to examine the broader health effects of administering the hepatitis B vaccine at birth. Researchers have planned to involve approximately 14,000 newborns, with one group receiving the vaccine shortly after birth and another receiving it later, at around six weeks of age. The project has attracted attention because the two groups would follow different vaccination schedules. Critics argue that delaying the birth dose for some babies could expose them to a preventable infection, particularly in a country where hepatitis B remains a significant public health concern. The research has been associated with Danish researchers and has received funding from the United States government. However, the funding and scientific objectives do not remove the requirement for authorization from the country where the study would take place. The central question remains whether the proposed design can meet accepted standards for scientific necessity, informed consent and the protection of newborn participants. International Health Experts Raise Ethical Concerns The World Health Organization has previously expressed significant concerns about the proposed trial, particularly the possibility that some newborns could be denied timely access to a vaccine with an established record of safety and effectiveness. According to the WHO, administering the hepatitis B vaccine within 24 hours of birth is an important measure for preventing mother-to-child transmission. Infection acquired during childbirth can develop into a chronic condition, increasing the risk of serious liver disease, including cirrhosis and liver cancer later in life. The organization has argued that research involving a control group that does not receive an established intervention requires a strong scientific justification and appropriate ethical protections. These concerns have made the Guinea-Bissau proposal a subject of wider international debate. Why Hepatitis B Prevention Matters Hepatitis B is a viral infection that affects the liver and can cause both short-term and lifelong illness. Transmission can occur from an infected mother to her baby during childbirth, making early prevention particularly important. Guinea-Bissau faces considerable challenges in expanding healthcare services and improving vaccination coverage. Public health experts have emphasized that strengthening access to established preventive measures could help protect newborns and reduce the long-term burden of liver disease. The debate over the trial also raises broader questions about medical research in lower-income countries, including whether participating communities receive adequate protection and whether research priorities reflect their healthcare needs. What Happens Next? The immediate priority is to establish the trial’s regulatory status and determine whether any revised proposal could meet the country’s scientific and ethical requirements. Further clarification from Guinea-Bissau’s authorities and the institutions involved will be important in determining the project’s future. For now, the government’s denial makes clear that reports of approval should not be treated as confirmation of official authorization. Any decision to proceed must follow the appropriate review and approval procedures. The controversy highlights a fundamental principle of medical research: scientific investigation must not come at the expense of participant safety. As discussions continue, protecting newborns, respecting national authority and maintaining public confidence in vaccination programmes remain central concerns. Developed, Researched & Published by PK-News.com PK-News Digital News & Research Desk This report is based on publicly available information concerning the proposed study and the government’s clarification as of October 14, 2026.

Patient Dies in Nairobi After Travelling From DRC Through Uganda; 28 Contacts Identified NAIROBI, KENYA — October 8, 2026: Kenya has confirmed its first imported case of Bundibugyo Ebola virus disease after a Kenyan citizen who had been living in the Democratic Republic of Congo (DRC) died in Nairobi following his arrival in the country. Kenya's Ministry of Health said the patient had been living in the DRC, where he became ill approximately a month before travelling to Uganda and then onward to Kenya. The case has triggered an intensified public-health response, with authorities identifying 28 contacts, including family members and healthcare workers who cared for the patient. Officials are also tracing passengers and crew members who travelled on the same flight. Patient Travelled From DRC to Nairobi According to Kenya's Ministry of Health, the patient travelled by road from the DRC to Kampala, Uganda, before boarding Jambojet Flight 8523 to Nairobi. He arrived at Jomo Kenyatta International Airport on October 3 at approximately 1:10pm. After arriving in Nairobi, he was taken to Nairobi Hospital, where he was isolated and assessed after developing symptoms consistent with Ebola. Health officials said his symptoms included fever, chills, fatigue, muscle pain, painful swallowing, sore throat and bleeding beneath the skin at injection sites. Samples were subsequently tested independently by Kenya's National Virology Reference Laboratory and the Kenya Medical Research Institute, with both confirming Bundibugyo Ebola virus disease. Patient Dies Despite Treatment The patient received supportive medical treatment but later died on the night of October 5. Kenyan authorities said his burial was conducted under special Ebola safety protocols designed to prevent transmission of the virus. The World Health Organization confirmed that the burial took place according to Kenya's safe and dignified burial procedures. 28 Contacts Identified Kenyan health authorities have so far identified 28 people who had contact with the patient. Those contacts include family members and healthcare workers who were involved in his care. Officials are monitoring the identified contacts and making quarantine arrangements for people considered to be at risk. Authorities are also tracing 23 passengers and four crew members who travelled on the same flight from Uganda to Nairobi. The contact-tracing operation is considered critical because identifying potentially exposed people quickly can help prevent further transmission. Kenya Strengthens Ebola Surveillance Kenya had already maintained a heightened state of alert since the Ebola outbreak began in the DRC in May. The Ministry of Health said that by October 6 it had screened 652,584 travellers and tested 267 samples through five laboratories. The screening effort involved the National Virology Reference Laboratory, Kenya Medical Research Institute laboratories in Nairobi and Kisumu, and mobile laboratories operating at the Busia and Lwakhakha border points. The government has now intensified surveillance and response measures following the confirmed case. WHO Supports Kenya's Response The World Health Organization (WHO) is working with Kenyan authorities to strengthen the response and prevent additional transmission. WHO said the response includes enhanced screening at high-risk points of entry, case investigation, contact monitoring, risk communication and community engagement. The agency said rapid detection and coordinated action will be important in preventing the virus from gaining a foothold in Kenya. DRC Faces a Serious Ebola Outbreak The Kenyan case is linked to the ongoing Ebola outbreak in the Democratic Republic of Congo. The DRC is currently experiencing an outbreak of Bundibugyo virus disease, a relatively rare species of Ebola virus. International reporting indicates that the outbreak has produced thousands of confirmed cases and more than 4,000 deaths, making it one of the most serious Ebola outbreaks recorded in the country. The outbreak has also spread into areas affected by conflict and population displacement, creating additional difficulties for healthcare workers and disease-control teams. North Kivu Raises Concern Health responders have warned about a worsening situation in parts of eastern DRC, particularly North Kivu, where the outbreak has been expanding. The region's insecurity, population movement, limited healthcare infrastructure and community mistrust have complicated efforts to identify cases and conduct safe burials. International health organisations have warned that the outbreak requires a rapid and coordinated response to prevent additional cross-border transmission. Concerns Over Cross-Border Travel The Kenyan case has also raised questions about how the patient travelled from the DRC through Uganda before reaching Nairobi. Reuters reported that the journey exposed weaknesses in border and airport screening systems, while Kenyan authorities are investigating how the patient passed through several screening points without being identified as an Ebola case. Officials have suggested that symptoms may not always be detected through routine temperature screening, particularly during the early stages of illness. The situation highlights the importance of accurate health declarations, effective border surveillance and rapid communication between countries during an infectious-disease outbreak. Uganda Monitors the Situation The patient's route through Uganda has also prompted attention from health authorities there. Uganda previously reported Ebola cases connected to the DRC outbreak but was declared free of the disease in August after completing its response period. WHO said Uganda's latest outbreak had included imported cases from the DRC as well as limited local transmission among contacts and healthcare workers. Authorities in the region are therefore monitoring the situation closely as Kenya investigates the patient's movements and contacts. What Is Bundibugyo Ebola? Bundibugyo virus is one of the viruses that can cause Ebola disease. Ebola can spread through direct contact with the blood or other bodily fluids of an infected person, including after death. Symptoms can include fever, weakness, muscle pain, vomiting and diarrhoea, with severe illness potentially involving bleeding. Because symptoms can initially resemble other illnesses, early identification and detailed travel and exposure histories are important during an outbreak. Kenya's Response Enters a Critical Phase The immediate priority for Kenyan authorities is to identify everyone who may have been exposed to the patient and monitor them for symptoms. The government, WHO and other health partners are working to strengthen surveillance, laboratory testing, isolation and contact tracing. Authorities are also expected to continue monitoring airports and border crossings connected to countries affected by the outbreak. No Evidence Yet of Wider Community Transmission At the time of the latest official update, Kenya had confirmed one imported Ebola case. The identification of contacts does not mean that those individuals have Ebola; they are being monitored because of their potential exposure to the confirmed patient. Health officials are therefore focusing on rapid follow-up and testing to determine whether any additional infections have occurred. Regional Health Alert Kenya's first imported case demonstrates how quickly infectious diseases can cross national borders when people travel between outbreak-affected areas. The case has prompted renewed attention to regional preparedness across East and Central Africa. WHO has emphasised that early detection, contact tracing, isolation and community cooperation remain essential tools for preventing a larger outbreak. PK-News.com International Health Coverage PK-News.com is closely monitoring the Ebola situation in Kenya, the Democratic Republic of Congo and the wider African region. This article has been developed, researched and prepared by the PK-News.com Digital News & Research Desk using information from the Kenyan Ministry of Health, WHO and international reporting. Developed, Researched & Published by PK-News.com Muhammad Ibraheem — Founder & Lead Architect PK-News.com Pakistan & World News • Breaking News • Live TV • Blogs • Products • Digital Technology

FIT & TRIM ORGANIC GREEN TEA is a refreshing herbal green tea blend designed for people who want to include a simple, enjoyable tea routine in their daily lifestyle. Made with carefully selected green tea ingredients, it offers a light and refreshing taste that can be enjoyed hot or cold. Whether you drink it in the morning, during the day, or after a meal, FIT & TRIM ORGANIC GREEN TEA can be a convenient addition to your everyday wellness routine. Enjoy it as part of a balanced lifestyle that includes nutritious food, regular physical activity, and adequate hydration. Key Features: 🌿 Organic green tea blend 🍵 Refreshing and easy to prepare 💚 Suitable for a daily tea routine 🔥 A convenient alternative to sugary beverages 🥗 Best enjoyed alongside a balanced lifestyle For Order: 📞 0333-9339001

Rawalpindi — September 22, 2026 | PK News Former Pakistan Prime Minister and PTI founder Imran Khan remains incarcerated at Adiala Jail, while reports about his health continue to draw public and political attention. The latest reported medical examination took place on September 20, when a special medical team from the Pakistan Institute of Medical Sciences (PIMS), including an ophthalmologist, examined Khan at the jail. According to reports citing medical and jail sources, doctors checked his blood pressure, cholesterol and eyesight. No new publicly confirmed medical emergency was reported following the examination. However, detailed medical findings have not been publicly released. Therefore, Khan’s complete current medical condition cannot be independently established from the information publicly available. 🏥 What We Know As of September 22, 2026: 🩺 Khan has reportedly undergone a recent medical examination at Adiala Jail. 👁️ An ophthalmologist examined his eyesight. 🩸 Doctors reportedly checked his blood pressure and cholesterol. ⚠️ No new publicly confirmed medical emergency has been reported after the September 20 examination. 📋 Detailed medical results have not been made public. Meanwhile, Khan’s family and supporters have continued to raise concerns about his access to medical care and meetings. Authorities have maintained that he is receiving medical monitoring. Reports also said that his cousin reached Adiala Jail on September 22 but was not permitted to meet him that day. 📌 Current Picture The available information indicates that Imran Khan has recently been examined by a medical team and remains under medical monitoring. Because a complete, independently verifiable medical report has not been publicly released, claims describing his condition as either completely healthy or seriously ill should be treated cautiously. PK News — PK-News.com Pakistan • Politics • Imran Khan • PTI

At least 20 people, including children, have been killed after a heavily damaged building collapsed in Gaza City, while rescue teams continue searching through the rubble for survivors and missing residents. The collapse occurred during the night when several families were reportedly inside the b

Trials for a vaccine for the Bundibugyo strain are ongoing as DRC authorities try to control the Ebola outbreak.

pBird eggs intercepted in homemade incubators at Johannesburg airport as officials try to halt wildlife trafficking/ppSouth African police have arrested two Thai nationals in separate incidents for allegedly attempting to smuggle endangered parrot eggs out of the country as authorities try to stem the tide of wildlife trafficking./ppA 50-year-old Thai national was arrested at OR Tambo international airport in Johannesburg on 20 August, carrying 50 bird eggs in a homemade incubator in a hand-luggage bag, South Africas environment ministry said in a a href"https://www.dffe.gov.za/mediarelease/arrest_allegedwildlifetrafficker"statement/a./p a href"https://www.theguardian.com/world/2026/aug/26/south-african-police-arrest-two-thai-men-smuggling-parrot-eggs"/a

A fire erupted early Wednesday in a nursery for newborns at a major government hospital in Pakistan's capital, killing 14 babies, according to hospital officials and the government.

pWest African country reports 46 suspected cases in outbreak declared in July, amid fears virus may be spreading undetected/ppMore than half of the mpox cases reported in Guinea-Bissau have been among children, local authorities have said, almost two months since the country announced an epidemic./ppA national outbreak was declared on 4 July, just over a week after a 27-year-old woman became the first confirmed case of mpox in the west African country. Since then, there have been seven confirmed cases and 46 suspected cases. Half of those patients have been children, with 16 under the age of four./p a href"https://www.theguardian.com/global-development/2026/aug/24/children-half-mpox-disease-cases-guinea-bissau-epidemic-spreads-west-africa"/a

Scientists say the growing El Nio weather pattern is an "unprecedented event" and means 2027 is likely to be the world's hottest year on record.